We thank Esposito et al. (1) for their comments regarding our analysis (2). It is indeed logical that baseline insulin regimen should have some power in predicting HbA1c change, perhaps particularly in insulin-naïve people with diabetes. The primary A1chieve results do report that the mean reduction in HbA1c associated with starting a basal insulin plus insulin aspart regimen was −2.8% (−31 mmol/mol) in insulin-naïve participants, compared with −2.2% (−24 mmol/mol) with biphasic aspart, −2.1% (−23 mmol/mol) with insulin detemir, and −2.3% (−25 mmol/mol) with insulin aspart alone (statistical comparisons across groups were not conducted due to the observational design) (3). Nevertheless, in this current analysis, baseline insulin regimen did not appear to have strong predictive power, contrary to the analysis by Esposito and colleagues (4). However, we note that in studies in which regimens have been directly compared, little difference is found between insulins—this being true for insulin analogs in the Treating To Target in Type 2 Diabetes (4-T) study (5) and for different basal insulins in a host of treat-to-target studies (6,7). The large improvement in HbA1c in A1chieve (3), and to a rather good level for routine care, may then be leaving little room for differentiating between insulins. In any case, it is reassuring to know that appropriate insulin use, irrespective of regimen, in patients with type 2 diabetes with poor blood glucose control can be associated with marked improvements in vascular risk factors (3). It is also reassuring that, as mentioned by Esposito et al. (1), the predictors of HbA1c response derived from meta-analyses of published randomized controlled trials are similar to this A1chieve analysis and others from routine clinical care around the world.
Duality of Interest. Novo Nordisk sponsored the A1chieve study and funded medical writing assistance. P.D.H., M.I.H., Z.A.L., and G.G.G. have received funding from Novo Nordisk (and in some cases from other insulin manufacturers) for themselves or their institutions for research, educational, and advisory activities. C.S. and J.-W.C. are employees of Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.
Clinical trial reg. no. NCT00869908, clinicaltrials.org.